Europe
It takes money to develop new, innovative treatments and this morning, multiple companies have announced significant fundraises. A summary of each financing round is below.
Artios Pharma Limited has entered into a global research collaboration with Novartis for the purpose of discovering and validating next-generation DDR targets and enhancing Novartis’ radioligand therapies.
At this time Vaccitech hasn’t priced its offering, although the report suggests they might sometime this month.
In mid-March, more than a dozen countries suspended the deployment of the AstraZeneca-Oxford University vaccine after incidences of blood clots were reported.
Please check out the biopharma industry’s COVID-19 stories that are trending for April 6, 2021.
In order to have full control of J&J’s product, the production of the AstraZeneca vaccine, which was being conducted at the same facility, will move elsewhere.
It was a busy week for clinical trial news. Here’s a look.
It’s something of the holy grail—run whole genome sequencing on a sample of a person’s blood and identify their risk for disease, all quickly and affordably. Oxford, England’s Genomics, founded in 2014 out of Oxford University by Sir Peter Donnelly, may be getting close.
A current Phase III trial of the Pfizer-BioNTech COVID-19 vaccine has confirmed the protection remains high for at least six months after the second dose. In a statement, Pfizer and BioNTech reported the vaccine was 91.3% effective against the disease.
In a statement, the company said, “Bristol Myers Squibb is in compliance with all applicable tax rules and regulations. We work with leading experts in this area and will continue to work cooperatively with the IRS to resolve this matter. Beyond that, we don’t comment on ongoing regulatory matters.”
PRESS RELEASES